The 1 analysts offering 12-month price forecasts for Timber Pharmaceuticals Inc have a median target of 12.00, with a high estimate of 12.00 and a low estimate of 12.00. The median estimate represents a +1,000.92% increase from the last price of 1.09.
The current consensus among 1 polled investment analysts is to Hold stock in Timber Pharmaceuticals Inc. This rating has held steady since January, when it was downgraded from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.96
Reporting Date TBD
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.